Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.
School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
Nucleic Acids Res. 2024 Jun 24;52(11):6360-6375. doi: 10.1093/nar/gkae316.
Although DNA-PK inhibitors (DNA-PK-i) have been applied in clinical trials for cancer treatment, the biomarkers and mechanism of action of DNA-PK-i in tumor cell suppression remain unclear. Here, we observed that a low dose of DNA-PK-i and PARP inhibitor (PARP-i) synthetically suppresses BRCA-deficient tumor cells without inducing DNA double-strand breaks (DSBs). Instead, we found that a fraction of DNA-PK localized inside of nucleoli, where we did not observe obvious DSBs. Moreover, the Ku proteins recognize pre-rRNA that facilitates DNA-PKcs autophosphorylation independent of DNA damage. Ribosomal proteins are also phosphorylated by DNA-PK, which regulates pre-rRNA biogenesis. In addition, DNA-PK-i acts together with PARP-i to suppress pre-rRNA biogenesis and tumor cell growth. Collectively, our studies reveal a DNA damage repair-independent role of DNA-PK-i in tumor suppression.
虽然 DNA 依赖性蛋白激酶抑制剂(DNA-PK-i)已被应用于癌症治疗的临床试验中,但 DNA-PK-i 在肿瘤细胞抑制中的生物标志物和作用机制仍不清楚。在这里,我们观察到低剂量的 DNA-PK-i 和聚腺苷二磷酸核糖聚合酶抑制剂(PARP-i)联合抑制 BRCA 缺陷型肿瘤细胞,而不会诱导 DNA 双链断裂(DSBs)。相反,我们发现一部分 DNA-PK 定位于核仁内部,在那里我们没有观察到明显的 DSBs。此外,Ku 蛋白识别促进 DNA-PKcs 自动磷酸化的前 rRNA,而无需 DNA 损伤。核糖体蛋白也被 DNA-PK 磷酸化,从而调节前 rRNA 的生物发生。此外,DNA-PK-i 与 PARP-i 一起抑制前 rRNA 的生物发生和肿瘤细胞的生长。总之,我们的研究揭示了 DNA-PK-i 在肿瘤抑制中的一种不依赖于 DNA 损伤修复的作用。